Moomoo AI 已提取核心信息
On December 31, 2023, a Schedule 13G was filed with the SEC by Ameriprise Financial, Inc. and several associated entities, collectively referred to as the Ameriprise Entities, regarding their holdings in Altimmune, Inc. The filing indicates that Ameriprise Financial, Inc., along with TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC Financing Ltd, Threadneedle Asset Management Limited, and Threadneedle Investment Services Limited, have a shared voting and dispositive power over a significant number of shares in Altimmune. Specifically, Ameriprise Financial, Inc. reported shared voting and dispositive power over 4,183,682 shares, representing 7.79% of the class, while the other entities each reported shared power over 4,013,211 shares, representing 7.47% of the class. The entities are organized under the laws of Delaware, England, and Wales. The filing was certified by Michael G. Clarke, Senior Vice President of Ameriprise Financial, Inc., on February 14, 2024, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.
On December 31, 2023, a Schedule 13G was filed with the SEC by Ameriprise Financial, Inc. and several associated entities, collectively referred to as the Ameriprise Entities, regarding their holdings in Altimmune, Inc. The filing indicates that Ameriprise Financial, Inc., along with TAM UK International Holdings Limited, Threadneedle Holdings Limited, TAM UK Holdings Limited, Threadneedle Asset Management Holdings Limited, TC Financing Ltd, Threadneedle Asset Management Limited, and Threadneedle Investment Services Limited, have a shared voting and dispositive power over a significant number of shares in Altimmune. Specifically, Ameriprise Financial, Inc. reported shared voting and dispositive power over 4,183,682 shares, representing 7.79% of the class, while the other entities each reported shared power over 4,013,211 shares, representing 7.47% of the class. The entities are organized under the laws of Delaware, England, and Wales. The filing was certified by Michael G. Clarke, Senior Vice President of Ameriprise Financial, Inc., on February 14, 2024, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune, Inc.
2023 年 12 月 31 日，Ameriprise Financial, Inc. 和几家关联实体（统称为 Ameriprise 实体）就其在 Altimmune, Inc. 的股份向美国证券交易委员会提交了附表13G。该文件显示，Ameriprise Financial, Inc. 以及TAM 英国国际控股有限公司、TAM 英国控股有限公司、Threadneedle 资产管理控股有限公司、TC 融资有限公司、Threadneedle 资产管理有限公司和 Threadneedle 投资服务有限公司，拥有共同投票权和决定权控制Altimmune的大量股份。具体而言，Ameriprise Fi...展开全部
2023 年 12 月 31 日，Ameriprise Financial, Inc. 和几家关联实体（统称为 Ameriprise 实体）就其在 Altimmune, Inc. 的股份向美国证券交易委员会提交了附表13G。该文件显示，Ameriprise Financial, Inc. 以及TAM 英国国际控股有限公司、TAM 英国控股有限公司、Threadneedle 资产管理控股有限公司、TC 融资有限公司、Threadneedle 资产管理有限公司和 Threadneedle 投资服务有限公司，拥有共同投票权和决定权控制Altimmune的大量股份。具体而言，Ameriprise Financial, Inc.报告了对4,183,682股股票的共享投票权和处置权，占该类别的7.79％，而其他实体则报告了对4,013,211股股票的共享权力，占该类别的7.47％。这些实体根据特拉华州、英格兰和威尔士的法律组建。该文件于2024年2月14日获得Ameriprise Financial, Inc.高级副总裁迈克尔·克拉克的认证，称这些股票是在正常业务过程中收购的，不是为了改变或影响Altimmune, Inc.的控制权。
有用
没用